CHMP recommends approval of generic memantine product (Maruxa®)

Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) has recommending the granting of a marketing authorisation for Maruxa®, intended for the treatment of patients with moderate to severe Alzheimer's disease. Maruxa® is a generic of Ebixa®, which has been authorised in the EU since 15 May 2002.   Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR), and will be available after the marketing authorisation has been granted by the European Commission.
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news